文献速递胸部肿瘤

帕博利珠单抗联合化疗致未化疗非鳞NSCLC患者肺炎的多中心回顾性队列研究

Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
PubMed 文献 · Eur J Cancer · 2021-04-20

该多中心回顾性队列研究纳入299例未化疗的晚期非鳞非小细胞肺癌患者,接受铂类+培美曲塞+帕博利珠单抗治疗。全级别肺炎发生率为12.4%(95%CI 8.9-16.7),≥3级为3.3%(95%CI 1.6-6.1)。校正不死时间偏倚后,肺炎与更短的无进展生存期(HR 1.99,95%CI 1.07-3.69,P=0.03)和总生存期(HR 3.03,95%CI 1.12-8.20,P=0.03)独立相关。

要点

  • 全级别肺炎发生率12.4%,≥3级肺炎发生率3.3%。
  • 肺炎与更短的无进展生存期和总生存期独立相关。
  • 真实世界中该联合治疗相关肺炎发生率高于既往报道。

核心结论

  • 真实世界中帕博利珠单抗联合化疗相关肺炎发生率高于既往报道,并导致更差的生存结局。

研究设计与样本

  • 36中心回顾性队列研究,纳入299例未化疗的晚期非鳞非小细胞肺癌患者,接受铂类+培美曲塞+帕博利珠单抗治疗。

主要发现

  • 全级别肺炎37例(12.4%,95%CI 8.9-16.7),≥3级肺炎10例(3.3%,95%CI 1.6-6.1)。
  • 联合治疗开始后90天内发生全级别肺炎21例(7.0%,95%CI 4.4-10.5),≥3级肺炎9例(3.0%,95%CI 1.4-5.6)。
  • 中位治疗失败时间5.9个月(95%CI 5.0-6.8),中位无进展生存期7.5个月(95%CI 6.5-8.7)。
  • 校正不死时间偏倚后,肺炎与更短的无进展生存期(HR 1.99,95%CI 1.07-3.69,P=0.03)和总生存期(HR 3.03,95%CI 1.12-8.20,P=0.03)独立相关。

临床怎么用

  • 在真实世界临床实践中,对接受帕博利珠单抗联合化疗的非鳞非小细胞肺癌患者需更加关注肺炎的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the extensive use of the combination of cytotoxic chemotherapy and programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors for cancer treatment, the incidence and characteristics of pneumonitis caused by this combination therapy have not been examined in clinical settings. METHODS: We conducted a 36-centre, retrospective cohort study in patients with chemo-naïve advanced non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed and pembrolizumab between December 2018 and June 2019. RESULTS: The study comprised 299 patients. The most frequent grade ≥3 non-hematologic adverse event was pneumonitis. There were 37 patients (12.4%, 95% CI 8.9-16.7) with all-grade pneumonitis and 10 (3.3%, 95% CI 1.6-6.1) with grade ≥3 pneumonitis. Of these, 21 (7.0%, 95% CI 4.4-10.5) and 9 patients (3.0%, 95% CI 1.4-5.6) developed all-grade and grade ≥3 pneumonitis within 90 days after initiating the combination therapy, respectively. The median time to treatment failure and progression-free survival was 5.9 (95% CI 5.0-6.8) and 7.5 (95% CI 6.5-8.7) months, respectively. In the survival analysis after adjusting for immortal time bias, pneumonitis was independently associated with shorter progression-free survival (HR 1.99, 95% CI 1.07-3.69, P = 0.03) and overall survival (HR 3.03, 95% CI 1.12-8.20, P = 0.03). CONCLUSIONS: Treatment-related pneumonitis occurred at a higher rate in the real-world population than that reported previously; it led to worse survival outcomes. Pneumonitis requires more attention. Additional studies are required to improve the safety of this combination therapy. TRIAL REGISTRATION NUMBER: UMIN000038084.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fujimoto D, Miura S, Yoshimura K, et al. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. Eur J Cancer. 2021. PMID: 33892408. doi:10.1016/j.ejca.2021.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。